A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, dose escalation study to evaluate tolerability, safety,
pharmacokinetics and efficacy in patients with BRAF V600 mutant advanced solid tumor by
HL-085 plus Vemurafenib treatment.